“…[ 13 ] Single institution | 36 | 2000–2011 | 91.7% | ALND (91.7%), TM (25.0%), no breast surgery (75.0%) | Breast (91.7%), RNI (77.8%) | 0.0% | 5-yr OS 100.0% | N1 (77.8%), N2 (16.7%), N3 (5.6%) | McCartan et al. [ 14 ] | Single institution | 38 | 1996–2011 | 100.0% | ALND + WBRT (65.8%) ALND + TM (34.2%) | Breast (100%), RNI (55.3%), chest wall (46.2%) | 8% (only in WBRT group) | 77.0% for TM, 10-yr DFS 67.0% for WBRT | N1 (57.9%), N2 (31.6%), N3 (10.5%) |
The present study | Multicenter | 66 | 2001–2013 | 100.0% | ALND + BCT (100.0%) | Breast (18.2%), Breast + RNI (75.7%), RNI (6.1%) | 9.1% | 92.1% at 5-yrs, DFS 80.6% at 10-yrs | Included 12 patients with SCN or IMN metastasis |
Abbreviation: MRI, magnetic resonance imaging; RT, radiotherapy; ALND, axillary lymph node dissection; TM, total mastectomy NR, not reported; LR, locoregional; NCDB, the National Cancer Database of the United States; OS, overall survival; SEER, the Surveillance, Epidemiology and End Results Program; BCS, breast-conserving surgery; RNI, regional lymph node irradiation; DFS, disease-free survival; SCN, supraclavicular lymph nodes. a years of patient’s accrual or periods of study inclusion.…”